Trials / Active Not Recruiting
Active Not RecruitingNCT05772286
Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted With MPLA Liposomes, in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted With MPLA Liposomes, in Healthy, HIV-Uninfected Adults
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
Study to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted with MPLA Liposomes, in Healthy, HIV-Uninfected Adults
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 763SIP8/MPLA-5 vaccine | 763SIP8/MPLA-5 vaccine at day 0, week 8, week 24 and week 48. |
Timeline
- Start date
- 2023-07-24
- Primary completion
- 2025-06-01
- Completion
- 2025-06-01
- First posted
- 2023-03-16
- Last updated
- 2024-07-10
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT05772286. Inclusion in this directory is not an endorsement.